Fewer than one in 10 patients that would benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it issues its inaugural guidance on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is urging broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key barriers to universal availability to the injections that can assist patients in reducing substantial body mass, explains the body.
GLP-1 Therapy Scarcity
Despite the current most optimistic case, the production of GLP-1 therapies could only cover around 100 million people – less than 10% of those who need them, according to the health organization.
The guideline calls on countries and companies to increase availability, by measures such as patent sharing.
Exclusive production rights on semaglutide – the core component of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Obesity Drugs Operate
The injections imitate a biological compound to slow digestion, reduce hunger and boost the sense of being full so people reduce food intake.
Individuals commonly begin shedding pounds within a few weeks of beginning the regular doses.
Research suggests patients may put most of the weight back on within a year of stopping the treatment, because their typical food cravings return.
Being carrying excess weight raises your risk for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight impacts people in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.
